Reactions Weekly, Journal Year: 2021, Volume and Issue: 1862(1), P. 307 - 307
Published: July 1, 2021
Language: Английский
Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)
Published: Jan. 21, 2025
Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide brief overview pembrolizumab-induced subacute lupus erythematosus (SCLE) cases literature. We 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment pembrolizumab. After 18 weeks (sixth cycle) immunotherapy, widespread pruritic erythematous rash evaluated as grade 3 appeared primarily on patient's limbs. Histopathological examination direct immunofluorescence showed characteristic features SCLE. The patient was treated oral prednisone 40 mg daily topical corticosteroids. In 2 weeks, her had cleared up significantly pruritus disappeared. an infrequent but recognized linked treatment.
Language: Английский
Citations
1
Archives of Dermatological Research, Journal Year: 2024, Volume and Issue: 316(10)
Published: Oct. 26, 2024
Language: Английский
Citations
6
Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11
Published: Feb. 1, 2024
Immune checkpoint inhibitor (ICI) use has been associated with numerous autoimmune side effects, known as immune related adverse events (irAEs). Cutaneous irAEs are common and affect up to 50% of patients treated ICIs. There have an increasing number cases reported in the literature regarding ICI-induced subacute cutaneous lupus erythematosus (SCLE). SCLE is important recognize it can result a delayed and/or prolonged skin reaction despite treatment discontinuation. We describe patient gastro-esophageal adenocarcinoma who developed following one cycle nivolumab treatment. A 75-year-old man presented our clinic new photo-distributed rash composed oval scaly pink papules plaques involving his chest arms. Despite topical corticosteroids, he emergency department 1 week later worsening rash. Skin biopsy showed vacuolar interface pattern, along superficial perivascular lymphocytic infiltrate, consistent drug eruption. The clinicopathological presentation was SCLE. Nivolumab discontinued due severity remitted systemic high potency steroids, hydroxychloroquine. Unfortunately, intraperitoneal metastatic disease, enrolled hospice care. In this paper, we highlight importance early identification irAE. review literature, including discussion on management also provided.
Language: Английский
Citations
4
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 28, 2025
The use of immune checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAE), which skin irAE is common, affecting up 50% ICI-treated patients. Although only a few cases subacute cutaneous lupus erythematosus (SCLE) have been reported in patients receiving anti-programmed death-1(anti-PD-1) immunotherapy, it important identify ICI-induced SCLE because may cause delayed and/or prolonged reactions even after treatment discontinuation. To date, no associated with Camrelizumab reported. We report case patient advanced non-small cell lung cancer (NSCLC) who gradually developed erythematous rashes on sun-exposed pruritus one course anti-PD-1 antibody combined chemotherapy. were initially considered as eczema, but did not improve symptomatic treatment. continued worsen the third treatment, and was unbearable. After testing, found positive anti-SS-A/Ro antibody, histological changes consistent erythematosus. controlled local systemic glucocorticoids, hydroxychloroquine, discontinuation therapy. be appearance regions, rapidly relieved by glucocorticoids hydroxychloroquine. It recommended perform early testing biopsy for diagnosis Unlike classic drug-related SCLE, develop multiple autoimmune diseases, caution should taken when using subsequent
Language: Английский
Citations
0
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(2), P. 252 - 252
Published: Feb. 15, 2024
Immune checkpoint inhibitors (ICIs) are the standard of care for a growing number malignancies. Unfortunately, they associated with broad range unique toxicities that mimic presentations primary autoimmune conditions. These adverse events termed immune-related (irAEs), which ICI-lupus erythematosus (ICI-LE) constitutes small percentage. Our review aims to describe available literature on ICI-LE and ICI treatment patients pre-existing lupus. Most diagnoses had findings only cutaneous lupus; four systemic lupus manifestations. Over 90% (27 29) cases received anti-PD-1/PDL-1 monotherapy, 1 combination therapy, anti-CTLA-4 treatment. About three-fourths (22 29 or 76%) were managed topical steroids, 13 (45%) hydroxychloroquine, 10 (34%) required oral corticosteroids. In our case series, none receiving therapy cancer flare their lupus, but few de novo irAE manifestations, all characterized as low-grade. The yielded seven flares from total 27 who ICI. manageable without need cessation.
Language: Английский
Citations
3
Journal of the American Academy of Dermatology, Journal Year: 2020, Volume and Issue: 84(3), P. 864 - 869
Published: Oct. 24, 2020
Language: Английский
Citations
21
Frontiers in Medicine, Journal Year: 2021, Volume and Issue: 8
Published: Nov. 4, 2021
Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers dramatically decreased mortality. However, with ICIs is directly associated immune-related adverse events (irAEs) because inflammation in off-target organs autoimmunity resulting from non-specific immune activation. These irAEs cause rheumatic diseases manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca Sjogen's syndrome, systemic lupus erythematosus. Early diagnosis these will improve outcomes quality life for patients. The induced by requires multidisciplinary cooperation among physicians. Furthermore, underlying mechanisms are not fully understood it difficult to predict evaluate side effects precisely. In this review, we summarize available studies findings about irAEs, focusing mainly on clinical manifestations, epidemiology, possible mechanisms, guiding principles treating irAEs.
Language: Английский
Citations
19
Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(17), P. 5648 - 5648
Published: Aug. 30, 2023
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with various clinical forms, including the subtypes of discoid (DLE) and subacute cutaneous (SCLE). The altered function programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) axis in CLE pathogenesis has been suggested. Here, soluble forms PD-1 (sPD-1) PD-L1 (sPD-L1) were explored untreated DLE SCLE. Levels sPD-1 sPD-L1 determined by enzyme-linked immunosorbent assay serums 21 DLE, 18 SCLE, 13 systemic (SLE) patients 20 healthy controls (HCs). Differences between patient groups HCs, association activity symptoms sPD-1/sPD-L1 levels analyzed Mann-Whitney U-test Spearmann's correlation. Regarding levels, no statistically significant differences found SCLE groups, nor compared to HCs. As for sPD-L1, a significantly lower level was group HC (p = 0.027 p 0.009, respectively). In SLE, higher HCs 0.002). No symptom CLE. Alterations inhibitory effect on T-cell might elucidate
Language: Английский
Citations
4
Acta Dermato Venereologica, Journal Year: 2024, Volume and Issue: 104, P. adv40801 - adv40801
Published: Sept. 30, 2024
Abstract is missing (Short Communication)
Language: Английский
Citations
1
Dermatitis, Journal Year: 2021, Volume and Issue: 34(3), P. 201 - 208
Published: Aug. 18, 2021
As treatment with immune checkpoint inhibitors (CPIs) for cancer increases, so has the incidence of immune-related cutaneous adverse events (irCAEs). These toxicities can significantly impact quality life and may be dose-limiting. Current guidelines irCAEs offer only corticosteroids or CPI discontinuation. Evidence supports biologic immunomodulatory therapies when fail need avoidance. A review literature from 2010 to 2020 yielded 45 articles, resulting in 185 irCAEs, including bullous pemphigoid-like eruption (n = 55), psoriasis/psoriasiform dermatitis 41), maculopapular rash 31). Treatments included immunomodulators, intravenous immunoglobulin, aprepitant, acitretin, tetracyclines, agents. Overall, 92.3% patients saw improvement resolution their rash. Bullous eruptions were treated a tetracycline +/- niacinamide (94.7% success [18/19]), omalizumab (100% [7/7]), rituximab [10/10]). Although prospective research is required, this provides comprehensive list successful, non-corticosteroid options improve compliance lifesaving therapy.
Language: Английский
Citations
8